Maackia amurensis seed lectin inhibits oral squamous cell carcinoma tumorigenesis by suppressing N6-methyladenosine modification–mediated SRY-box transcription factor 2 expression
Journal of International Medical Research · 2026-06 · 54 (6)
DOI: 10.1177/03000605261457780 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of International Medical Research, online erschienen am 16.06.2026. Verfasst von Yong Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stomatology, The Second Hospital of Hebei Medical University, China. Hauptthemen laut MEDLINE: Mouth Neoplasms, Carcinoma, Squamous Cell, SOXB1 Transcription Factors, Adenosine. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Hebei Province.
Abstract (Originalsprache)
Objective
Studies have indicated that combining Maackia amurensis seed lectin with first-line chemotherapeutic agents enhances the efficacy of treatment for oral squamous cell carcinoma. The study aimed to investigate the underlying mechanism of Maackia amurensis seed lectin in the treatment of oral squamous cell carcinoma.
Methods
Gene Expression Omnibus dataset mining, reverse transcription–quantitative polymerase chain reaction, and western blot analysis were performed to identify the expression of SRY-box transcription factor 2, methyltransferase 3, and YTH domain-containing protein 1 in oral squamous cell carcinoma. The N6-methyladenosine methylation levels of SRY-box transcription factor 2 were detected though methylated RNA immunoprecipitation. The effects of Maackia amurensis seed lectin and SRY-box transcription factor 2 on oral squamous cell carcinoma cells were determined via Cell Counting Kit-8 and colony formation assays.
Results
The results demonstrated that increased expression of SRY-box transcription factor 2 in oral squamous cell carcinoma is correlated with elevated levels of N6-methyladenosine modification, and treatment with Maackia amurensis seed lectin reduces the N6-methyladenosine modification level and SRY-box transcription factor 2 expression. Moreover, overexpression of SRY-box transcription factor 2 reversed the inhibitory effects of Maackia amurensis seed lectin on oral squamous cell carcinoma cell proliferation and colony formation.
Conclusions
Maackia amurensis seed lectin may inhibit oral squamous cell carcinoma cell proliferation by suppressing N6-methyladenosine modification–mediated SRY-box transcription factor 2 expression, thereby improving chemotherapy sensitivity in oral squamous cell carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stomatology, The Second Hospital of Hebei Medical University, China.
- Department of Pathology, The Second Hospital of Hebei Medical University, China.
- Department of Radiotherapy, The Second Hospital of Hebei Medical University, China.
ORCID-Profile: Haiyan Yang
Förderung
- Natural Science Foundation of Hebei Province
Zitieren
APA
Du, Y., Yang, H., Lian, H., Li, D., Liu, W., Zhao, L., & Zhang, Y. (2026). Maackia amurensis seed lectin inhibits oral squamous cell carcinoma tumorigenesis by suppressing N6-methyladenosine modification–mediated SRY-box transcription factor 2 expression. Journal of International Medical Research, 54(6). https://doi.org/10.1177/03000605261457780
Vancouver
Du Y, Yang H, Lian H, Li D, Liu W, Zhao L, et al. Maackia amurensis seed lectin inhibits oral squamous cell carcinoma tumorigenesis by suppressing N6-methyladenosine modification–mediated SRY-box transcription factor 2 expression. Journal of International Medical Research. 2026;54(6). doi:10.1177/03000605261457780
BibTeX
@article{Du2026,
author = {Du, Yong and Yang, Haiyan and Lian, Hongguang and Li, Dan and Liu, Weina and Zhao, Linyuan and Zhang, Yufeng},
title = {Maackia amurensis seed lectin inhibits oral squamous cell carcinoma tumorigenesis by suppressing N6-methyladenosine modification–mediated SRY-box transcription factor 2 expression},
journal = {Journal of International Medical Research},
year = {2026},
volume = {54},
number = {6},
doi = {10.1177/03000605261457780}
}
EUVIMED